Posted by Michael Wonder on 04 Aug 2018
ICER updated report on targeted treatments for plaque psoriasis finds guselkumab and risankizumab offer superior health benefit compared with TNFα inhibitors
3 August 2018 - Policy recommendations repeat call for insurers to minimise step therapy requirements on these treatments that are priced in alignment with clinical benefits, but cautions manufacturers against the ongoing price increases that are beginning to threaten the cost-effectiveness of entire therapy class.
The ICER today released a final condition update report and Report-at-a-Glance on targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis. ICER first reviewed treatments for plaque psoriasis in 2016.
This update incorporates new clinical data and cost information for previously reviewed therapies, and includes analyses of more recently approved medications guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), and certolizumab pegol (Cimzia, UCB), as well as risankizumab (AbbVie), which is currently being reviewed by the FDA.
